A new thiopurine s-methyltransferase haplotype associated with intolerance to azathioprine

Journal of Clinical Pharmacology

Volumn 53, Issue 1, 2013, Pages 67-74

  Colleoni, Lara ^a   Kapetis, Dimos ^a   Maggi, Lorenzo ^a   Camera, Giorgia ^a   Canioni, Eleonora ^a   Cavalcante, Paola ^a   De Rosbo, Nicole Kerlero ^a   Baggi, Fulvio ^a   Antozzi, Carlo ^a   Confalonieri, Paolo ^a   Mantegazza, Renato ^a   Bernasconi, Pia ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Azathioprine; Haplotype; Myasthenia gravis; Single nucleotide polymorphism; Thiopurine S methyltransferase

Indexed keywords

AZATHIOPRINE; STEROID; THIOPURINE METHYLTRANSFERASE;

ARTICLE; BLOOD TOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXON; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HETEROZYGOTE; HUMAN; INTRON; ITALY; LEUKOPENIA; LIVER TOXICITY; MACROCYTIC ANEMIA; MAJOR CLINICAL STUDY; MYASTHENIA GRAVIS; NEUTROPENIA; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; RASH; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH DISEASE; TREATMENT RESPONSE;

AZATHIOPRINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HAPLOTYPES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITALY; METHYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84877865447     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011435989     Document Type: Article

References (40)

1. Richman D, Agius M. Treatment of autoimmune myasthenia gravis. Neurology . 2003;61(12):1652-1661.
2. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol. 1988;235(8): 449-453.
3. Cendrowski W. Therapeutic trial of Imuran (azathioprine) in multiple sclerosis. Acta Neurol Scand . 1971;47(2):254-260.
4. Suarez-Almazor M, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2000 (4):CD001461.
5. Lee A, Farrell G. Mechanism of azathioprine-induced injury to hepatocytes: roles of glutathione depletion and mitochondrial injury. J Hepatol. 2001;35(6):756-764.
6. Coulthard S, Hogarth L, Little M, et al. The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol Pharmacol. 2002;62(1):102-109.
7. Lennard L, Lilleyman J, Van Loon J, Weinshilboum R. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet . 1990;336(8709):225-229.
8. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene . 2006;25(11):1629-1638.
9. de Boer N, Mulder C, van Bodegraven A. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth J Med . 2005;63(11):444-446.
10. Lennard L, Van Loon J, Weinshilboum R. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989;46(2):149-154.
11. Krynetski E, Schuetz J, Galpin A, et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A . 1995;92(4):949-953.
12. Weinshilboum R, Sladek S. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32(5):651-662.
13. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997;62(1):60-73.
14. Garat A, Cauffiez C, Renault N, et al. Characterisation of novel defective thiopurine S-methyltransferase allelic variants. Biochem Pharmacol. 2008;76(3):404-415.
15. Kham SK, Soh CK, Aw DC, Yeoh AE. TPMT*26 (208F L), a novel mutation detected in a Chinese. Br J Clin Pharmacol. 2009;68(1):120-123.
16. Feng Q, Vannaprasaht S, Peng Y, et al. Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme. Biochem Pharmacol . 2010;79(7):1053-1061.
17. Appell ML, Wennerstrand P, Peterson C, Hertervig E, Mårtensson LG. Characterization of a novel sequence variant, TPMT*28, in the human thiopurine methyltransferase gene. Pharmacogenet Genomics. 2010;20(11):700-707.
18. Weinshilboum R. Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase. Cell Mol Neurobiol. 2006;26(4-6):539-561.
19. Ujiie S, Sasaki T, Mizugaki M, Ishikawa M, Hiratsuka M. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMTz.ast;2-z.ast;24). Pharmacogenet Genomics . 2008;18(10):887-893.
20. Jaretzki AR, Barohn R, Ernstoff R, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology . 2000;55(1):16-23.
21. Ansari A, Arenas M, Greenfield S, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(8):973-983.
22. Schaeffeler E, Lang T, Zanger U, Eichelbaum M, Schwab M. Highthroughput genotyping of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem. 2001;47(3):548-555.
23. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics . 2005;21(2):263-265.
24. González JR, Armengol L, Solé X, et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics . 2007;23(5):644-645.
25. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet. 2002;70(2):425-434.
26. Palaniswamy R, Teglund S, Lauth M, Zaphiropoulos PG, Shimokawa T. Genetic variations regulate alternative splicing in the 5 ' untranslated regions of the mouse glioma-associated oncogene 1, Gli1. BMC Mol Biol. 2010;11:32.
27. Hull J, Campino S, Rowlands K, et al. Identification of common genetic variation that modulates alternative splicing. PLoS Genet. 2007;3(6):e99.
28. Rochette J, Le Gac G, Lassoued K, Férec C, Robson K. Factors influencing disease phenotype and penetrance in HFE haemochromatosis. Hum Genet. 2010;128(3):233-248.
29. Meisler M, O'Brien J, Sharkey L. Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. J Physiol. 2010;588(pt 11):1841-1848.
30. Smith M, Marinaki A, Arenas M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther. 2009;30(4):375-384.
31. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol. 1998;125(4):879-887.
32. Ameyaw M, Collie-Duguid E, Powrie R, Ofori-Adjei D, McLeod H. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet. 1999;8(2):367-370.
33. McLeod H, Pritchard S, Githang'a J, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics . 1999;9(6):773-776.
34. Rossi A, Bianchi M, Guarnieri C, Barale R, Pacifici G. Genotypephenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol. 2001;57(1):51-54.
35. Schaeffeler E, Zanger U, Eichelbaum M, et al. Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem. 2008;54(10):1637-1647.
36. Cheon J, Kim J, Kim B, et al. Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases. Hepatogastroenterology . 2009;56(90):421-423.
37. Lennard L, Maddocks J. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6-thioguanine, in human red blood cells. J Pharm Pharmacol . 1983;35(1):15-18.
38. Cara C, Pena A, Sans M, et al. Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice. Med Sci Monit. 2004;10(11):RA247-RA254.
39. Li F, Fridley B, Matimba A, et al. Ecto-5 '-nucleotidase (NT5E) and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos. 2010;38(12):2329-2338.
40. Ban H, Andoh A, Imaeda H, et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol . 2010;45(10):1014- 1021.